CSF2 and colorectal cancer: Patients with advanced colorectal cancer subjected to treatment with AEXs plus GM-CSF demonstrated a strong anti-tumor cytotoxic T-lymphocyte response against the carcinoembryonic antigen (181), a colorectal cancer biomarker (182).